Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of “Hold” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received an average recommendation of “Hold” from the twenty-two analysts that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $23.7391.

NTLA has been the subject of several research analyst reports. Barclays reduced their target price on shares of Intellia Therapeutics from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, October 28th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $14.00 target price (down previously from $21.00) on shares of Intellia Therapeutics in a report on Tuesday, October 28th. Wedbush set a $9.00 target price on shares of Intellia Therapeutics in a report on Thursday, October 30th. William Blair lowered shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 27th. Finally, Guggenheim lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, October 27th.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares in the company, valued at $960,523.08. This represents a 3.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William J. Chase bought 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were acquired at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the transaction, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. This represents a 288.24% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NTLA. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Intellia Therapeutics during the 1st quarter worth approximately $98,000. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Intellia Therapeutics by 51.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock worth $140,000 after acquiring an additional 6,722 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Intellia Therapeutics by 30.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 16,798 shares of the company’s stock worth $112,000 after acquiring an additional 3,935 shares during the period. D.A. Davidson & CO. lifted its holdings in shares of Intellia Therapeutics by 76.2% during the 1st quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock worth $185,000 after acquiring an additional 11,250 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of Intellia Therapeutics by 9.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 73,150 shares of the company’s stock worth $520,000 after acquiring an additional 6,496 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $13.57 on Friday. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -2.89 and a beta of 2.44. The company has a 50-day simple moving average of $17.21 and a 200 day simple moving average of $12.46. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. The business had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. Intellia Therapeutics’s revenue was up 104.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.52) EPS. Sell-side analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.